# A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer

> **NCT03901469** · PHASE2 · TERMINATED · sponsor: **Zenith Epigenetics** · enrollment: 115 (actual)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **DRUG:** ZEN003694
- **DRUG:** Talazoparib

## Key facts

- **NCT ID:** NCT03901469
- **Lead sponsor:** Zenith Epigenetics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-26
- **Primary completion:** 2024-03-07
- **Final completion:** 2024-03-07
- **Target enrollment:** 115 (ACTUAL)
- **Why stopped:** Parts 1 and 2 and Expansion Cohort C were completed. Expansion Cohorts A and B were discontinued based on results from an interim futility analysis and not due to safety concerns.
- **Last updated:** 2025-10-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03901469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03901469, "A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03901469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*